SHYNDEC(SH:600420)2023-04-25 16:00Financial Performance - The net profit attributable to shareholders increased by 130.87% compared to the same period last year, driven by a stabilization in the pharmaceutical terminal market[7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses rose by 157.99%, with a decrease in expense ratios by 5.45 percentage points year-on-year[7]. - The net profit attributable to shareholders for Q1 2023 was ¥179,223,645.37, representing a significant increase of 130.87% from the previous year[37]. - The net profit for the first quarter of 2023 was RMB 274,261,401.19, compared to RMB 136,080,784.29 in the same period of 2022, showing an increase of about 101.9%[48]. - The company's net profit for Q1 2023 was $18.71 million, a decrease from $157.78 million in Q1 2022, reflecting a decline of 88.2%[63]. - The company reported a comprehensive income of $18.68 million for Q1 2023, down from $158.18 million in Q1 2022, a decline of 88.2%[63]. Revenue and Sales - Operating revenue for Q1 2023 reached ¥3,417,169,160.61, up from ¥3,244,221,809.47 in Q1 2022, reflecting a growth in sales[21]. - The company's operating revenue for Q1 2023 was ¥254,001,223.34, a decrease of 43.2% compared to ¥446,817,438.79 in Q1 2022[31]. - Cash received from sales of goods and services in Q1 2023 totaled ¥2,458,359,184.90, a decrease of 10.4% compared to ¥2,744,038,557.81 in Q1 2022[50]. Cash Flow and Liquidity - Cash flow from operating activities decreased by 35.33% year-on-year, primarily due to a reduction in cash inflow from sales orders settled with advance payments in Q4 2022[7]. - The net cash flow from operating activities for Q1 2023 was ¥269,560,307.91, a decrease of 35.33% compared to the same period last year[37]. - The company experienced a net cash outflow from financing activities of ¥797,465,602.21 in Q1 2023, compared to a smaller outflow of ¥217,174,350.82 in Q1 2022[28]. - Cash inflow from operating activities for Q1 2023 was $397.19 million, up from $328.82 million in Q1 2022, representing a 20.8% increase[57]. - Net cash flow from operating activities for Q1 2023 was -$8.57 million, a significant decline from $165.22 million in Q1 2022[57]. - Cash and cash equivalents at the end of Q1 2023 were $2.38 billion, up from $1.10 billion at the end of Q1 2022, an increase of 116.7%[65]. Assets and Liabilities - The company reported a total asset value of ¥18,957,972,176.28 as of March 31, 2023, down from ¥19,630,346,096.40 at the end of 2022[18]. - The total assets at the end of Q1 2023 were ¥18,957,972,176.28, a decrease of 3.43% from the end of the previous year[37]. - The total liabilities decreased, with short-term borrowings dropping significantly from ¥321,138,719.45 to ¥25,026,736.06[18]. - The total liabilities decreased to RMB 6,531,019,691.95 from RMB 7,477,624,438.48, indicating a reduction of approximately 12.7%[46]. - Total liabilities decreased to $3.93 billion as of March 31, 2023, from $5.22 billion at the end of 2022, a reduction of 24.7%[61]. Equity and Retained Earnings - The company's total equity increased to RMB 12,426,952,484.33 as of March 31, 2023, up from RMB 12,152,721,657.92 at the end of 2022, representing a growth of approximately 2.3%[46]. - The company's retained earnings rose to RMB 5,065,125,677.15 as of March 31, 2023, compared to RMB 4,885,902,031.78 at the end of 2022, marking an increase of approximately 3.7%[46]. Research and Development - Research and development expenses for Q1 2023 were ¥110,631,302.54, compared to ¥116,995,102.84 in Q1 2022, indicating a focus on cost control[21]. - Research and development expenses for Q1 2023 were ¥17,406,876.57, slightly down from ¥18,962,920.22 in Q1 2022[31]. Dividends and Shareholder Returns - The company paid dividends to minority shareholders amounting to ¥5,107,617.57 in Q1 2023, up from ¥2,828,123.93 in Q1 2022[28]. - The basic earnings per share for Q1 2023 was ¥0.1529, an increase of 102.25% year-over-year[37]. - Basic earnings per share (EPS) for Q1 2023 was ¥0.1529, up from ¥0.0756 in Q1 2022, indicating an increase of 102.4%[49].